Panax Clinical Research

Miami Lakes, Florida 33104

9 studies enrolling now · 57 studies all time

What they study most

Aging Frailty, Alzheimer Disease, Atherosclerotic Cardiovascular Disease, Autoimmune and Chronic Inflammatory Diseases, COVID-19, Cardiovascular Disease, Cardiovascular Diseases, Chikungunya Virus, Chlamydia Trachomatis Infection, Chronic Gout, Chronic Hepatitis D Infection, Chronic Kidney Disease

Studies at this site

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events — Recruiting now
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets — Recruiting now
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) — Recruiting now
A Study of Dotinurad Versus Allopurinol in Participants With Gout — Recruiting now
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout — Recruiting now
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Recruiting now
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy — Recruiting now
A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment — Recruiting now
Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency — Recruiting now
A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants — Completed
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia — Completed
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage — Completed
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD) — Completed
A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function — Completed
Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis. — Completed
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk — Completed
A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants. — Completed
A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza — Completed
A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function — Completed
An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function — Completed
A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II — Completed
Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D) — Completed
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment — Completed
A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function — Completed
A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy — Completed
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza — Completed
HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes — Completed
Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH) — Completed
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections — Completed
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis — Running, not enrolling
Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function — Completed
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years — Completed
A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT) — Completed
IMM-BCP-01 in Mild to Moderate COVID-19 — Stopped early
A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease — Completed
A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease — Completed
Study to Evaluate the Equivalence of Estradiol Vaginal Cream to Reference Standard in the Treatment of Vaginal Atrophy — Completed
A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy — Completed
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD) — Completed
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) — Completed
Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects — Completed
Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients — Completed
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis — Status unconfirmed
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness — Completed
A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus — Completed
Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty — Completed
Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers — Completed
Diabetic Gastroparesis Study 05 — Stopped early
PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment — Completed
A Study to Determine the Signs and Symptoms That Impact Daily Life of Participants With Irregular Sleep-Wake Rhythm Disorder — Completed